中华临床医师杂志(电子版)
中華臨床醫師雜誌(電子版)
중화림상의사잡지(전자판)
CHINESE JOURNAL OF CLINICIANS(ELECTRONIC VERSION)
2013年
4期
1674-1677
,共4页
张明明%张洪战%沈洋%张英峰%胡冰
張明明%張洪戰%瀋洋%張英峰%鬍冰
장명명%장홍전%침양%장영봉%호빙
药物洗脱支架%曲安奈德%聚乳酸%缓释
藥物洗脫支架%麯安奈德%聚乳痠%緩釋
약물세탈지가%곡안내덕%취유산%완석
Drug-eluting stents%Triamcinolone acetonide%Polylactic glycolic acid%Sustained-release
目的制作一种新型可以缓释曲安奈德的胆道支架,观察带药支架药物释放的规律。方法将曲安奈德和聚( DL-乳酸-羟基乙酸)共聚物( PLGA)粉末以20%的带药浓度溶于两者的共同溶剂四氢呋喃(THF)中,并将6 Fr胆道引流管浸剪成数个50 mm段泡于上述溶剂中,10 min后取出真空烘干,常温避光保存。通过测重计算支架所载曲安奈德的质量;采用磷酸盐缓冲液( PBS,pH 7.4)将曲安奈德稀释为系列标准液,对240 nm紫外分光峰面积进行相关分析。将曲安奈德支架放入8 ml PBS中,置于37℃的恒温摇床中持续浸泡48 h,然后换新鲜的PBS重复浸泡,直至第40天。以标准PBS液为对照组,对第1~40天留取的浸出液进行色谱分析,计算曲安奈德在浸出液中的浓度。结果称量测得平均每根支架上曲安奈德的负载量为510μg,单位面积的载药量为1.63μg/mm2。曲安奈德均能从支架表面持续释放,前5 d浓度波动在6.32~8.78μg /ml,前5 d共释放曲安奈德180.61μg,占总释放量的47.23%,之后浓度平稳波动在1.85~3.51μg/ml,第23天后开始降低,第33天的洗脱浓度为0.53μg/ml,随后即不可测得。结论用PLGA作为药物载体能成功制备曲安奈德药物胆道洗脱支架;体外研究表明该药物洗脱支架可持续稳定释放曲安奈德超过30 d。
目的製作一種新型可以緩釋麯安奈德的膽道支架,觀察帶藥支架藥物釋放的規律。方法將麯安奈德和聚( DL-乳痠-羥基乙痠)共聚物( PLGA)粉末以20%的帶藥濃度溶于兩者的共同溶劑四氫呋喃(THF)中,併將6 Fr膽道引流管浸剪成數箇50 mm段泡于上述溶劑中,10 min後取齣真空烘榦,常溫避光保存。通過測重計算支架所載麯安奈德的質量;採用燐痠鹽緩遲液( PBS,pH 7.4)將麯安奈德稀釋為繫列標準液,對240 nm紫外分光峰麵積進行相關分析。將麯安奈德支架放入8 ml PBS中,置于37℃的恆溫搖床中持續浸泡48 h,然後換新鮮的PBS重複浸泡,直至第40天。以標準PBS液為對照組,對第1~40天留取的浸齣液進行色譜分析,計算麯安奈德在浸齣液中的濃度。結果稱量測得平均每根支架上麯安奈德的負載量為510μg,單位麵積的載藥量為1.63μg/mm2。麯安奈德均能從支架錶麵持續釋放,前5 d濃度波動在6.32~8.78μg /ml,前5 d共釋放麯安奈德180.61μg,佔總釋放量的47.23%,之後濃度平穩波動在1.85~3.51μg/ml,第23天後開始降低,第33天的洗脫濃度為0.53μg/ml,隨後即不可測得。結論用PLGA作為藥物載體能成功製備麯安奈德藥物膽道洗脫支架;體外研究錶明該藥物洗脫支架可持續穩定釋放麯安奈德超過30 d。
목적제작일충신형가이완석곡안내덕적담도지가,관찰대약지가약물석방적규률。방법장곡안내덕화취( DL-유산-간기을산)공취물( PLGA)분말이20%적대약농도용우량자적공동용제사경부남(THF)중,병장6 Fr담도인류관침전성수개50 mm단포우상술용제중,10 min후취출진공홍간,상온피광보존。통과측중계산지가소재곡안내덕적질량;채용린산염완충액( PBS,pH 7.4)장곡안내덕희석위계렬표준액,대240 nm자외분광봉면적진행상관분석。장곡안내덕지가방입8 ml PBS중,치우37℃적항온요상중지속침포48 h,연후환신선적PBS중복침포,직지제40천。이표준PBS액위대조조,대제1~40천류취적침출액진행색보분석,계산곡안내덕재침출액중적농도。결과칭량측득평균매근지가상곡안내덕적부재량위510μg,단위면적적재약량위1.63μg/mm2。곡안내덕균능종지가표면지속석방,전5 d농도파동재6.32~8.78μg /ml,전5 d공석방곡안내덕180.61μg,점총석방량적47.23%,지후농도평은파동재1.85~3.51μg/ml,제23천후개시강저,제33천적세탈농도위0.53μg/ml,수후즉불가측득。결론용PLGA작위약물재체능성공제비곡안내덕약물담도세탈지가;체외연구표명해약물세탈지가가지속은정석방곡안내덕초과30 d。
Objective To produce a new kind of biliary stent with Triamcinolone-eluting and observe the law of drug delivery from the stent .Methods The powder both the Triamcinolone and polylactic glycolic acid (PLGA)dissolved in the common solvent tetrahydrofuran (THF)with a drug concentration of 20%.6F biliary soaked in the above solvents .After 10 minutes,removed the vacuum drying ,and stored at room temperature .Calculated the quality of the stent contained in Triamcinolone by measuring changes in the quality .PBS buffer ( pH 7.4 ) diluted Triamcinolone for the standard solution and analyzed the ultraviolet peak area at 240 nm.Triamcinolone-eluting stents were soaked in PBS ,placed in shaker with a constant temperature of 37 ℃continuing soaked 48 h,and then soaked in fresh PBS solution until 40 d.Standard PBS solutions as the control group , the chromatographic analysis of specimens from the leaching solution for 1-40 d, calculated the concentration of Triamcinolone in the leaching solution.Results The quality of Triamcinolone contained in the stent was detected .Triamcinolone on the stent of capacity was up to 510 μg;per unit area contained in the drug amount was 1.63 μg/mm2 .Triamcinolone could be sustained-release from the stent surface.The first five days the quality release from the stent was 180.61 μg,was 47.23%of the total amount release from the stent then it fluctuated within 1.85-3.51 μg/ml.The concentration of Triamcinolone began to decrease from the 23th day,and it was 0.53 μg/ml on the 33th day,it can′t be detected in the later days.Conclusions Triamcinolone-eluting biliary stents can be successful prepared by polylactic glycolic acid as a drug carrier .In vitro study shows that the drug-eluting stents can sustainable and stable release of Triamcinolone over 30 d.